- Home
- EXEL
EXEL
Exelixis Inc.
as 05-20-2024 11:34am EST
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 6.1B | IPO Year: | 2000 |
| Target Price: | $26.64 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.64 | EPS Growth: | 33.33 |
| 52 Week Low/High: | $18.64 - $24.34 | Next Earning Date: | 04-30-2024 |
| Revenue: | $1,846,646,000 | Revenue Growth: | 10.98% |
| Revenue Growth (this year): | 6.11% | Revenue Growth (next year): | 8.39% |
Share on Social Networks:
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Garber Alan M | EXEL | Director | Mar 21 '24 | Sell | $24.01 | 19,205 | $461,112.05 | 35,703 | SEC Form 4 |
| Haley Patrick J. | EXEL | EVP, Commercial | Feb 23 '24 | Sell | $21.45 | 47,020 | $1,008,579.00 | 384,866 | SEC Form 4 |
| JOHNSON DAVID EDWARD | EXEL | Director | Feb 21 '24 | Buy | $20.70 | 190,000 | $3,932,734.00 | 1,100,730 | SEC Form 4 |
| Hessekiel Jeffrey | EXEL | EVP, General Counsel & Sec | Dec 13 '23 | Sell | $23.01 | 25,000 | $575,250.00 | 533,345 | SEC Form 4 |
| Hessekiel Jeffrey | EXEL | EVP, General Counsel & Sec | Nov 30 '23 | Sell | $22.06 | 25,000 | $551,500.00 | 558,345 | SEC Form 4 |
| Hessekiel Jeffrey | EXEL | EVP, General Counsel & Sec | Nov 30 '23 | Sell | $22.01 | 25,000 | $550,250.00 | 583,345 | SEC Form 4 |
| JOHNSON DAVID EDWARD | EXEL | Director | Nov 27 '23 | Buy | $21.61 | 120,409 | $2,602,038.49 | 910,730 | SEC Form 4 |
| JOHNSON DAVID EDWARD | EXEL | Director | Nov 27 '23 | Sell | $21.61 | 120,409 | $2,602,038.49 | 790,321 | SEC Form 4 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
MT Newswires
2 hours ago
Exelixis Settles Cabometyx Patent Litigation with Cipla
Business Wire
4 hours ago
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Morningstar Research
6 days ago
Analyst Report: Exelixis, Inc.
MT Newswires
6 days ago
Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target
Motley Fool
8 days ago
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Business Wire
13 days ago
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Zacks
14 days ago
Exelixis (EXEL) International Revenue Performance Explored
Morningstar Research
17 days ago